Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils?

Table 2 Risks and benefits of immediate resection versus neoadjuvant therapy followed by resection for resectable pancreatic cancer in the era of coronavirus disease 2019

	Immediate pancreatic resection	Neoadjuvant chemoradiation
Patients	(1) Increased perioperative morbidity and mortality; and (2) Exposure risk to COVID-19 with excess contacts	(1) Better completion rates; (2) Avoidance of surgery in those chemo-resistant and rapidly progressing; (3) Less caregivers can be in direct contact with the patient; and (4) No data is available weighing the gravity of immunosuppressive chemotherapy versus immediate surgery on morbidity and mortality in the era of COVID-19
Health care providers	(1) Exposure risk of surgical personnel and postoperative caregivers; and (2) Most hospitals are still in the process of implementing local mitigating measures in the surgical settings	(1) Exposure risk of medical, radiation oncology, and infusion center personnel; and (2) Delay of surgery until better mitigating protocols are implemented by local surgical operations

COVID-19: Coronavirus disease 2019.